Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Chronic action of association of zidovudine, lamivudine and ritonavir on pregnant rats. A biologic assay
A. Wagner1,*, M. Uchiyama Nakamura2, R.S. Simões Simões3, R.M. Oliveira-Filho4, T.M. Pereira Fontes2, L.P. Fogarolli de Carvalho1, S. Espiridiao2, L. Kulay Jr.2
Show Less
1
Department of Obstetrics and Gynecology, University of José do Rosário Vellano, Alfenas (MG)
2
Department of Obstetrics and Gynecology, Federal University of São Paulo School of Medicine (UNIFESP-EPM), São Paulo (SP)
3
Department of Obstetrics and Gynecology, University of São Paulo Medical School, São Paulo (SP)
4
Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo (SP) (Brazil)
Clin. Exp. Obstet. Gynecol. 2011, 38(1), 28–32;
Published: 10 March 2011
Abstract
Purpose: To evaluate at term the effects of a highly active antiretroviral (HAAR) drug association administered during the entire period of rat pregnancy. Methods: Three groups (n = 10 each) of adult pregnant rats were treated with an oral solution of HAAR (Exp 1 = 10/5/20 mg/kg b.w.; Exp 2 = 30/15/60 mg/kg b.w.; Exp 3 = 90/45/180 mg/kg b.w.) from day “0” up to the 20th day of pregnancy. A fourth group served as a control. At term (20th day) the rats were killed under deep anesthesia and the number of implantations, resorptions, living fetuses, placentae and intrauterine deaths were recorded. Results: The highest HAAR doses caused lower maternal weight gain, lower litter weights, and lower placental weights compared to the control group. Conclusions: HAAR during the entire period of rat pregnancy can reduce maternal body weight gain and lower term placental weight.;">
Keywords
Rat
Pregnancy
Zidovudine
Lamivudine
Ritonavir